C2N Diagnostics launches new assay for Alzheimer’s disease

By The Science Advisory Board staff writers

May 19, 2022 -- C2N Diagnostics debuted a high resolution mass spectrometry-based plasma tau multianalyte assay (p-tau MAA) for research use only that can advance understanding of Alzheimer’s disease.

The assay uses a small sample of blood to measure different phosphorylated and nonphosphorylated forms of the tau protein, including those at the tau217 and tau181 sites. The assay builds on research demonstrating that interactions among abnormal tau and beta-amyloid proteins, as well as several other factors, play a role in Alzheimer's-related brain changes.

Researchers can now evaluate and characterize p-tau MAA's ability to identify Alzheimer's pathology at the early stages of Alzheimer's disease, C2N said.

Copyright © 2022 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here